Avalo Therapeutics Files Amendment to 8-K

TL;DR

AVLO filed an amendment to its 8-K, likely a clerical update, no major news.

AI Summary

Avalo Therapeutics, Inc. filed an amendment (Amendment No. 1) to its Form 8-K on March 27, 2024, which was filed on March 28, 2024. This amendment pertains to Item 9.01, Financial Statements and Exhibits, and was filed as of June 3, 2024. The filing does not appear to contain new substantive information beyond the initial filing's scope.

Why It Matters

This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information, though the specific nature of the update is not detailed in the provided text.

Risk Assessment

Risk Level: low — This is an amendment to a previous filing, likely for administrative or exhibit-related purposes, rather than a disclosure of new material events.

Key Numbers

• 001-37590 — SEC File Number (Identifies the company's filing history with the SEC)
• 45-0705648 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• Avalo Therapeutics, Inc. (company) — Registrant
• Cerecor Inc. (company) — Former company name
• March 27, 2024 (date) — Earliest event reported date
• March 28, 2024 (date) — Date of initial Form 8-K filing
• June 3, 2024 (date) — Filing date of the amendment

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market

Filing Documents

• avtx-20240327.htm (8-K/A) — 31KB
• ex-231eyconsent.htm (EX-23.1) — 2KB
• ex-991almataauditedfinanci.htm (EX-99.1) — 133KB
• ex-992almataproforma.htm (EX-99.2) — 131KB
• 0001628280-24-026140.txt ( ) — 447KB
• avtx-20240327.xsd (EX-101.SCH) — 2KB
• avtx-20240327_lab.xml (EX-101.LAB) — 21KB
• avtx-20240327_pre.xml (EX-101.PRE) — 12KB
• avtx-20240327_htm.xml (XML) — 3KB

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (a) Financial Statements of Business Acquired. The audited financial statements of Almata as of December 31, 2023 and for the period from April 28, 2023 (date of inception) to December 31, 2023 and the related notes are attached hereto as Exhibit 99.1 and incorporated herein by reference. (b) Pro Forma Financial Information. Unaudited pro forma condensed combined financial information, which includes pro forma condensed combined statements of operations for the year ended December 31, 2023 and the three months ended March 31, 2024 and the notes related thereto, are filed as Exhibit 99.2 to this report and incorporated herein by reference. (d) Exhibits: Exhibit No. Description 23.1 Consent of Ernst & Young, LLP, Independent Registered Public Accounting Firm 99.1 Audited financial statements of Almata as of December 31, 2023 and for the period from April 28, 2023 (date of inception) to December 31, 2023. 99.2 Unaudited pro forma combined financial information of Almata and Avalo for the three months ended March 31, 2024 and for the year ended December 31, 2023. 104 The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: June 3, 2024 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 2

View Full Filing

View this 8-K/A filing on SEC EDGAR